biodefense

2008 ASM Biodefense and Emerging Disease Research Meeting

The American Society for Microbiology (ASM) will host its 2008 Biodefense and Emerging Diseases Research Meeting February 24-27, 2008 at the Baltimore Marriott Waterfront Hotel in Baltimore, MD. There is a continuing need for research that helps better protect the public against not only the...

United States Department of Defense Selects Ichor Medical Systems to Develop Biodefense Vaccine

SAN DIEGO--(BUSINESS WIRE)--Ichor Medical Systems, whose advanced electroporation system is being used worldwide to increase the effectiveness// of DNA drug and vaccine delivery, has been awarded a two-year contract valued at over $900,000 by the United States Department of Defense to assist the Un...

1957-58 Flu Pandemic Can Provide Clues to Planning for h1n1

... published in Biosecurity and Bioterrorism ahead of print at: http://www.liebertonline.com/toc/bsp/0/0 . Biosecurity and Bioterrorism: biodefense Strategy, Practice, and Science , a quarterly peer-reviewed journal, is published by Mary Ann Liebert, Inc. The Center for Biosecurity is a...

PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

... ANNAPOLIS, Md., July 27 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has signed definitive agreements for the i...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

... Defense's Defense Threat Reduction Agency (DTRA), and ramped up activities under this contract to assess bavituximab and other anti-PS antibodies for biodefense applications against viral hemorrhagic fevers. Continued to enroll and dose patients in an ongoing Phase I clinical trial of bavituximab in hep...

New Drug Fights Anthrax Toxin

... has provided solid data to support raxibacumab as a new candidate drug for biodefense and public health. "The most encouraging finding is that raxibacuma...ial public health threat," he said. "This paradigm of drug approval for biodefense agents provides a new way to address such threats, though questions remain ...

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller

...rostate cancer and endometriosis. Through its biodefense Division, DOR is developing biomedical countermeas...rsuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit va...s which are subject to performance, enter into any biodefense procurement contracts with the US Government or ot...

Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer

...re and Roche, respectively. In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under devel...

New accurate diagnostic test for swine H1N1 influenza using RT-PCR technology

...ys Stephen Higgs BSc, PhD, FRES, Editor-in-Chief of Vector-Borne and Zoonotic Diseases , and Associate Professor, Department of Pathology, Center for biodefense & Emerging Infectious Diseases, Sealy Center for Vaccine Development and WHO Collaborating Center for Tropical Diseases, University of Texas Medical B...

Response Biomedical Closes $12.65 million Unit Offering

...re and Roche, respectively. In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under devel...

biodefense in Medical Technology

Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents

CHICAGO, Aug. 21 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS ), today announced the commencement of its collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the lead governmental institute supporting biodefense research, under...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

...ng used to advance vaccines for cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, influenza, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP-compliant manufacturing facility is loca...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

...rostate cancer and endometriosis. Through its biodefense Division, DOR is developing biomedical countermeas...rsuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit va...s which are subject to performance, enter into any biodefense procurement contracts with the US Government or ot...

PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)

... ANNAPOLIS, Md., June 2 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has submitted a proposal to the Biomedical...

PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA

... ANNAPOLIS, Md., May 22 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company has submitted its comprehensive r...

AlphaVax Announces Promising Results in Melanoma Studies

... immunotherapy programs, AlphaVax is developing vaccine products for herpes simplex virus, influenza, respiratory syncytial virus, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Leno...

PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program

... ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it will be hosting a conference call for inve...

Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology

... ANNAPOLIS, Md., March 31 /PRNewswire-FirstCall/ --PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new mechanism of action data for Valortim(R) ...

DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

...rostate cancer and endometriosis. Through its biodefense Division, DOR is developing biomedical countermeas...rsuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit va...s which are subject to performance, enter into any biodefense procurement contracts with the US Government or ot...

PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)

... ANNAPOLIS, Md., Oct. 27 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE ALTERNEXT US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun in a U.S. Phas...

biodefense in Medical Dictionary

Bioterrorism

...ral pests, for ... Politics & Society > Bioterrorism Dictionary ... Bioterrorism - Key Documents - Documents from the Institute for ... biodefense and Bioterrorism ... Regionalization of Bioterrorism Preparedness and Response ... With the latest news, reference material, literature select...

biodefense in Biological News

ASM biodefense and emerging diseases research meeting

The American Society for Microbiology (ASM) will host its 2009 Biodefense and Emerging Diseases Research Meeting February 22-25, 2008 at the Baltimore Marriott Waterfront Hotel in Baltimore, MD. The purpose of this meeting is to bring together individuals who are carrying out research to def...

New NIAID grants strengthen national biodefense and emerging infectious diseases research network

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four-year grants totaling approximately $80 million for two new Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE). The grants to ...

Comprehensive biodefense text published

A new book, Biological Weapons Defense: Infectious Disease and Counterbioterrorism, deals with the intentional causality of disease. Published by Humana Press, this text is also available in e-Book. Many of the contributors come from the U.S. Army Medical Research Institute of Infectious Diseases (...

Disease diagnosis, biodefense among UH chemical research projects

With 33 presentations of original research that showcase applications ranging from early-stage disease diagnosis to fuel cells and batteries, the University of Houston will be well represented at the 229th National Meeting of the American Chemical Society (ACS), March 13 to 17 in San Diego. Found...

UCI awarded $45 million for infectious disease research

...nfectious disease research. The renewal grant, which is the campus's largest ever, went to the Pacific-Southwest Regional Center of Excellence for biodefense and Emerging Infectious Diseases Research and its director, Dr. Alan Barbour, a UCI infectious disease expert. Created in May 2005 with a four-year, ...

Purdue researcher invents molecule that stops SARS

...roup teamed with a research group led by Andrew Mesecar at the University of Illinois at Chicago. The National Institutes of Health infectious disease biodefense program selected the team and funded the research that has been published in the online version of the journal Proceedings of the National Academy of...

NIAID announces 25 new awards to develop radiation countermeasures

...ssigned NIAID the leadership role in managing basic research efforts to develop medical treatments and diagnostics for CBRN threats, and NIAID and the biodefense Advanced Research and Development Authority collaborate to promote product development of promising candidate countermeasures. NIAID also works closel...

American Society for Microbiology honors Walter Stamm

...ociety for Microbiology (ASM) sanofi-aventis U.S. Award will be presented to Walter Stamm, Associate Director, WWAMI Regional Center of Excellence for biodefense and Emerging Infectious Diseases, Seattle, Washington. Supported by an unrestricted grant from sanofi-aventis U.S., this award honors outstanding acc...

Breakthrough research turns the tide on water-borne pathogen

...nt from human IMPDH. They tested 40,000 compounds using the facilities of the National Screening Laboratory for the Regional Centers of Excellence in biodefense and Emerging Infectious Disease (NSRB/NERCE) at Harvard Medical School, and identified ten compounds that inhibited the parasite protein, but not the ...

Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports

...n to show up in horses and their human handlers in Australia. Experts who drew up the U.S. National Institute of Allergy and Infectious Diseases' biodefense Research Agenda have included both viruses as potential bioterror agents. "Theoretically, it's possible to go out into the field and collect Hendra...

biodefense in Biological Technology

New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague

HUBBARD, Ohio, April 13 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX) a biotechnology company, is pleased to provide the following information: An independent study has found that NanoLogix's BNP(TM) Ultra-Fast Identification Technology allows the viewing of anthrax cultures fo...

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting

ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a Phase II study of SparVax(TM) and pharmacokinetic (PK) data for Valorti...

Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury

DURHAM, N.C., Dec. 16 /PRNewswire/ -- Parion Sciences, Inc., a privately-held, development-stage pharmaceutical company dedicated to treating diseases resulting from the failure of the body's mucosal defenses, today announced that the National Institutes of Health (NIH) have awarded the company a ...

PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel

ANNAPOLIS, Md., Nov. 19 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has signed an agreement with Medison Pharma Ltd., to commercialize its biodefense p...

PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases

Panacea Biotec to Make a $13.1 Million Strategic Investment in PharmAthene ANNAPOLIS, Md., Sept. 30 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has entered int...

Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million

- Two-Year Contract from the Defense Threat Reduction Agency Will Fund the Advanced Development of Cethromycin as a Potential Broad-Spectrum Medical Countermeasure - CHICAGO, Aug. 13 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS ), to...

Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection

'United Kingdom Needs to Wake Up to Threat of Bioterrorism,' Says UK Board Member General Lord Guthrie BOSTON, April 22 /PRNewswire/ -- BioDefense Corp., the only company in the world to develop and deploy technology that can neutralize and destroy a biohazardous substance ...

PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit

Strategic Acquisition Creates Expanded Biodefense Pipeline ANNAPOLIS, Md., April 2, 2008 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP ) a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threa...

PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia

Strategic Acquisition Reinforces PharmAthene's Status as a Premier Biodefense Company; Creates Expanded Biodefense Pipeline ANNAPOLIS, Md., and TEES VALLEY, England, March 20 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company special...

Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference

CHICAGO, Jan. 3 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS ), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation, today announced that it will ...